← Human Trials & Peer-Reviewed Studies

Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.

Plain-language guide to PMID 15764170 (2004): clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID
15764170
Journal
Scandinavian journal of infectious diseases
Year
2004
Study type
Clinical Trial
Authors
Andersen O et al. (8 authors)
DOI
10.1080/00365540410021162

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

Three h GH-suppression tests using oral glucose were undertaken to determine dynamics of GH-secretion.

Why It Was Studied

Growth hormone (GH)-secretion in HIV-lipodystrophy is impaired; however, GH-sensitivity of GH-target tissues remains to be evaluated.

The researchers measured overnight fasting concentrations of GH-sensitive insulin-like growth-factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) including GH binding protein (GHBP), a marker of GH-receptor sensitivity, in antiretroviral treated HIV-infected patients with (LIPO) and without lipodystrophy (NONLIPO) and antiretroviral naive HIV-infected patients (NAIVE).

Who Took Part

The age groups tagged for this paper are adults, men only.

What Was Measured

Growth hormone (GH)-secretion in HIV-lipodystrophy is impaired; however, GH-sensitivity of GH-target tissues remains to be evaluated.

The researchers measured overnight fasting concentrations of GH-sensitive insulin-like growth-factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) including GH binding protein (GHBP), a marker of GH-receptor sensitivity, in antiretroviral treated HIV-infected patients with (LIPO) and without lipodystrophy (NONLIPO) and antiretroviral naive HIV-infected patients (NAIVE).

Topics PubMed links to this paper include Absorptiometry, Photon, Antiretroviral Therapy, Highly Active, Body Composition, Glucose, HIV Infections, HIV-Associated Lipodystrophy Syndrome and Human Growth Hormone.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2004 (Scandinavian journal of infectious diseases), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.